At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects
In Brief
A Phase 1 clinical trial evaluating aprepitant 165 mg, Comparator: aprepitant 185 mg, and 2 other interventions for Chemotherapy-Induced Nausea and Vomiting. Completed, enrolled 42 participants.
Detailed Summary
This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailability of oral aprepitant.
Study Details
Timeline
Interventions
Single dose of aprepitant 165 mg tablet in the fasted state during treatment period 1,2, or 3.
Single dose of aprepitant 185 mg tablet in the fasted state during treatment period 1, 2, or 3.
Single dose of fosaprepitant 150 mg intravenous infusion in the fasted state during treatment period 1,2, or 3.
Single dose of aprepitant 165 mg or 185 mg tablet in the fed state during treatment period 4.